Among these is anakinra, a recombinant IL-1R antagonist that inhibits both IL-1α and IL-1β, which has demonstrated comparatively positive outcomes in HS in both a short open-label trial and a randomized clinical trial [77,78]. The gene discussed is IL1A; the disease is histiocytic sarcoma.